Among metabolic agents, glucagon-like peptide-1 receptor (GLP-1R) agonists (e.g., semaglutide) reduce hepatic fat through weight loss, but evidence for fibrosis improvement remains insufficient (16); peroxisome proliferator-activated receptor (PPAR) agonists (e.g., pioglitazone) improve histological features of steatohepatitis, yet adverse effects (weight gain, edema, potential heart failure) constrain clinical utility (17); sodium-dependent glucose transporters-2 (SGLT-2) inhibitors ameliorate glucolipid metabolism but lack controlled trials assessing histological endpoints. The gene discussed is GLP1R; the disease is heart failure.